XML 28 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating expenses:    
Research and development $ 10,392 $ 12,705
Impairment of in-process research and development 5,990 0
In-process research and development 0 80,538
General and administrative 16,835 14,724
Transaction costs 0 5,765
Total operating expenses 33,217 113,732
Loss from operations (33,217) (113,732)
Other income (expenses):    
Loss on sale of NTN assets 0 (9,648)
Change in fair value of warrant liabilities 10,795 0
Loss on non-controlling investment (941) 0
Other (expense) income, net (1,171) 899
Total other income (expenses), net 8,683 (8,749)
Loss before income taxes (24,534) (122,481)
Provision for income taxes (45) (64)
Net loss (24,579) (122,545)
Series A preferred stock dividend (16) (16)
Net loss attributable to common stockholders $ (24,595) $ (122,561)
Net loss per common share - basic (in dollars per share) $ (8.06) $ (56.61)
Net loss per common share - diluted (in dollars per share) $ (8.06) $ (56.61)
Weighted average shares outstanding - basic (in shares) 3,051 2,165
Weighted average shares outstanding - diluted (in shares) 3,051 2,165